SCIENION and Anteo Partner
News Jul 25, 2015
SCIENION and Australian biotech company Anteo Technologies have announced that they have partnered to co-develop protein microarray consumables using Anteo’s proprietary Mix&Go™ technology. Mix&Go activated surface consumables improve functionality and stability of biological molecules.
The project will combine the advantages of the Mix&Go technology with the capability of SCIENION’s precision spotting sciFLEXARRAYER technology, with the objective of delivering more accurate results and better, longer-lasting and more cost effective diagnostics. The first targeted products of the Anteo and SCIENION collaboration will be activated glass and polymer slides.
Josh Soldo, VP Scientific Affairs at Anteo explains: “With SCIENION, we have found a partner with deep expertise in surface functionalization and protein spotting, and one with excellent products. As a result of our partnership, scientists will soon have the tools that they need to overcome the present limitations of protein arrays, and increase the performance of their arrays, while reducing the sample size needed to get results. In brief, we expect the partnership to yield more effective tests with better specificity.”
Holger Eickhoff, CEO of SCIENION, says: “As a very customer focused company, we always seek to expand the portfolio of solutions we can propose to help implement the various platform technologies that our customers bring to us. Anteo’s new coating technology will enable us to provide an even higher level of customer application support via unprecedented combinations of materials, surfaces and deposition technology. The perfect pairing of the right surface with the right dispensing is key to a successful application where a biological molecule is deposited to become attached to a surface. The expertise of both companies is very complementary, and together we will exploit the resulting synergies.”
Both SCIENION and Anteo will be in attendance at the AACC Annual Meeting and Clinical Lab Expo in Atlanta, GA, USA from July 26-30, 2015.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE